FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Canopy Growth's Free Cash Flow for the
three
months ended in Mar. 2026 was €-12.2 Mil. Canopy Growth's Revenue for the
three
months ended in Mar. 2026 was €44.9 Mil. Therefore, Canopy Growth's FCF Margin % for the quarter that ended in Mar. 2026 was -27.18%.
The historical rank and industry rank for Canopy Growth's FCF Margin % or its related term are showing as below:
HAM:11L'
s FCF Margin % Range Over the Past 10 Years
Min: -553.96 Med: -133.4 Max: -24.47
Current: -24.47
During the past 13 years, the highest FCF Margin % of Canopy Growth was -24.47%. The lowest was -553.96%. And the median was -133.40%.
HAM:11L's FCF Margin % is ranked worse than 83.51% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs HAM:11L: -24.47
Canopy Growth FCF Margin % Related Terms
Canopy Growth FCF Margin % Historical Data
* Premium members only.
The historical data trend for Canopy Growth's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Canopy Growth's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canopy Growth FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Canopy Growth's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Canopy Growth's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Canopy Growth (HAM:11L) has a FCF Margin % of -27.18% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Canopy Growth and its competitors. According to the industry distribution chart, Canopy Growth ranks #800 out of 958 companies in the Drug Manufacturers industry, placing it in the top 83.5%.
Is Canopy Growth's FCF Margin % too high?
Canopy Growth's current FCF Margin % is -27.18%. Based on the distribution chart, Canopy Growth ranks #800 out of 958 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Canopy Growth has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Canopy Growth's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Canopy Growth ranks #800 out of 958 companies for FCF Margin %. This places Canopy Growth in the lower half of its industry. The industry median FCF Margin % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Canopy Growth and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Canopy Growth's current FCF Margin % is -27.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canopy Growth stock overvalued right now?
Based on GuruFocus' analysis, Canopy Growth (HAM:11L) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.65, compared to a current price of €0.81 — trading 23.9% above its estimated fair value. The current FCF Margin % is -27.18%. Canopy Growth's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Canopy Growth (HAM:11L), the current FCF Margin % is -27.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Canopy Growth (HAM:11L) Overvalued in 2026?
Based on GuruFocus' analysis, Canopy Growth stock appears to be overvalued.
The current stock price of €0.81 is trading 23.9% above its estimated GF Value™ of €0.65.
GuruFocus considers Canopy Growth to be Modestly Overvalued.
Key valuation signals for HAM:11L:
FCF Margin %: -27.18%
GF Value™: €0.65 vs. price of €0.81 (23.9% above fair value)
No single metric tells the full story. See the HAM:11L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
60GF Score
Get the complete analysis for HAM:11L
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:11L has been successfully added to your 
